Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Tilray Brands Inc TLRY

Alternate Symbol(s):  T.TLRY

Tilray Brands, Inc. is a global lifestyle and consumer packaged goods company. The Company operates through four segments: Cannabis operations, Distribution business, Beverage alcohol business and Wellness business. The Cannabis operations, which encompasses the production, distribution, sale, co-manufacturing and advisory services of both medical and adult-use cannabis. The Beverage alcohol operations, which encompasses the production, marketing and sale of beverage alcohol products. The Distribution operations, which encompasses the purchase and resale of pharmaceuticals products to customers. The Wellness products, which encompasses hemp foods and cannabidiol (CBD) products. The Company offers a portfolio of adult-use brands and products and expands its portfolio to include new cannabis products and formats. Its brands include Good Supply, RIFF, Broken Coast, Solei, Canaca, HEXO, Redecan, Original Stash, Hop Valley, Revolver, Bake Sale, XMG, Mollo, and others.


NDAQ:TLRY - Post by User

Comment by okgonowon Mar 25, 2024 9:03am
78 Views
Post# 35950319

RE:April Fool's Day?

RE:April Fool's Day?

MediPharm Labs Provides Update on German Cannabis Legalization

T.LABS 
  • German federal states have voted to decriminalize the personal cultivation and use of cannabis.
  • The new legislation that takes effect April 1, 2024, also removes medical cannabis from the German narcotic list, removing access barriers for patients.

TORONTOMarch 25, 2024 /PRNewswire/ - MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in precision-based cannabinoids, is pleased to provide an update on German cannabis legalization.

MediPharm Labs Corp. Logo (CNW Group/MediPharm Labs Corp.)

Germany's upper house, the Bundesrat (made up of federal state delegates), passed legislation to partially legalize cannabis starting April 1, 2024. The new law will allow adults to cultivate, possess and store cannabis for their personal consumption. The law also removes medical cannabis from Germany's narcotic list, a change that is expected to remove barriers to patient access.

This historic change is a significant positive step in removing the stigma related to medical cannabis. The removal of cannabis from narcotic status will open the opportunity for more physicians, pharmacies, and patients to participate in the current German medical cannabis market.

MediPharm sees this having a positive impact on its already robust German business.

Summary of MediPharm Labs Business Operations in Germany

Beacon Medical GMBH

  • Beacon Medical is a wholly owned subsidiary of MediPharm Labs. Located in Potsdam, the business holds a suite of German GMP medical cannabis licenses to import, wholesale and distribute GMP cannabis products.
  • Beacon Medical is a medical product brand with distribution via German partners Adrex Pharma, Cansativa and Medical Pharma Resource.
  • Thus far in 2024, MediPharm has increased the German product approvals under the Beacon Medical brand from 5 to 14.

Turnkey Medical Cannabis Supply

  • Partnered with STADA, a large global consumer health and pharmaceutical company, as their exclusive medical cannabis supplier. MediPharm manufactures and distributes medical cannabis products to STADA customer pharmacies.
  • STADA currently holds the number two market share in medical cannabis oil sales.

Business to Business Supply

  • Starting with our first contract in 2019 with long-term partner Adrex Pharma, MediPharm supplies API and end products to various German-based companies.
  • This business line also includes GMP services, where MPL assists domestic and international companies in making their products compliant in our GMP facilities for the German export market.
  • The recent launch of our D9 THC isolate supply business (a monographed pharmaceutical commonly referred to as Dronabinol) has expanded 2024 sales, unlocking new distribution channels in Germany.

All of these German medical cannabis activities are supported by the Company's manufacturing sites in Barrie and Napanee, Ontario, which each maintain GMP licensing permitting export to Germany and other international jurisdictions.

Thank you to the cannabis advocates and Federal Government in Germany for leading this triumphant charge. Herzlichen Glckwunsch.


<< Previous
Bullboard Posts
Next >>